This is not an official government website.
© 2026 PLEJ LC. All rights reserved.
Congressional Daily Record
This section is a tribute, commemoration, or district-facing statement. It mentions legislation such as Designating July 15, 2026, as "Glioblastoma Awareness Day"..
Issued
June 23, 2026
senate side of the record
People
0
No members linked from this section
Legislation
1
Bills and resolutions linked from this section
Committees
0
No linked committees in this section
Senate Holds
0
No hold activity linked here
Source Document
Connected Data
Bills and resolutions
Source Control
Reader mode is for comprehension. The linked government PDF is the official published source.
Download official Senate Record PDFReturn to issue contextSENATE RESOLUTION 786—DESIGNATING JULY 15, 2026, AS “GLIOBLASTOMA
AWARENESS DAY”
Mr. GRAHAM (for himself, Mr. Kelly, Mr. Barrasso, Mr. Scott of South Carolina, Mr. Van Hollen, Mr. Markey, Ms. Warren, Mr. Coons, Mr. Gallego, and Mrs. Shaheen) submitted the following resolution; which was considered and agreed to:
S. Res. 786
Whereas it is estimated that more than 13,000 individuals
in the United States will be diagnosed with glioblastoma in
2026;
Whereas glioblastoma is—
(1) the most common malignant (cancerous) brain tumor,
accounting for approximately \1/2\ of all primary malignant
brain tumors; and
(2) the most aggressive, complex, difficult to treat, and
deadly type of brain tumor;
Whereas it is estimated that more than 10,000 individuals
in the United States will succumb to glioblastoma each year;
Whereas the 5-year survival rate for glioblastoma is only 7
percent, and the median survival rate following all diagnosed
cases is only 8 months;
Whereas glioblastoma is described as a disease that affects
the “essence of self”, as the treatment and removal of
glioblastoma presents significant challenges due to the
uniquely complex and fragile nature of the brain, the primary
organ in the human body that controls not only cognitive
ability, but also the actions of every organ and limb;
Whereas patients and caregivers play a critical role in
furthering research for glioblastoma;
Whereas, relative to patients with other types of cancers,
brain cancer patients pay the second highest out-of-pocket
costs for medical services in both the initial and end-of-
life phases of care;
Whereas, although research advances may fuel the
development of new treatments for glioblastoma, challenging
obstacles to accelerating progress toward new treatments for
glioblastoma remain, and there are no screening or early
detection methods;
Whereas, in 2021, significant changes were made to the
molecular characteristics of a glioblastoma diagnosis,
necessitating critical biomarker testing for patients
suspected of having a possible glioblastoma;
Whereas, although glioblastoma was first described in
medical and scientific literature in the 1920s, and despite
its devastating prognosis, only 5 drugs and 1 medical device
have
been approved by the Food and Drug Administration to
specifically treat glioblastoma since the 1920s, and the
mortality rates associated with glioblastoma have changed
little during the past 30 years;
Whereas, since the first Glioblastoma Awareness Day, the
National Cancer Institute established the Glioblastoma
Therapeutics Network (referred to in this preamble as
“GTN”) in 2020 as part of a national infrastructure to
enhance and support the discovery and development of
glioblastoma therapies available for multi-institutional GTN
teams to drive therapeutic agents through preclinical studies
and early phase clinical trials, which are necessary to
rapidly evaluate potential treatments to advance toward cures
and improved quality of life; and
Whereas there is a need for greater public awareness of
glioblastoma, including awareness of both—
(1) the urgent unmet medical needs of glioblastoma
patients; and
(2) the opportunities for research of, and treatment
advances for, glioblastoma: Now, therefore, be it
Resolved, That the Senate—
(1) designates July 15, 2026, as “Glioblastoma Awareness
Day”;
(2) encourages increased public awareness of glioblastoma;
(3) honors the individuals who have died from the
devastating disease of glioblastoma or are currently living
with the disease;
(4) supports efforts to develop better treatments for
glioblastoma that will improve the long-term prognosis for,
and the quality of life of, individuals diagnosed with the
disease;
(5) recognizes the importance of molecular biomarker
testing to the diagnosis and treatment of glioblastoma;
(6) expresses support for the individuals who are battling
brain tumors, as well as the families, friends, and
caregivers of those individuals;
(7) urges a collaborative approach to brain tumor research
among governmental, private, and nonprofit organizations,
which is a promising means of advancing the understanding and
treatment of glioblastoma; and
(8) encourages continued investments in glioblastoma
research and treatments, including through the Glioblastoma
Therapeutics Network and other existing brain tumor research
resources.